目的 探究醒脑静注射液联合胞磷胆碱钠注射液治疗急性脑梗死的临床疗效。方法 选择2016年8月-2018年3月德昌县人民医院收治的120例急性脑梗死患者作为研究对象，全部急性脑梗死患者随机分为对照组和治疗组，每组各60例。对照组静脉滴注胞磷胆碱钠注射液，0.5 g加入到生理盐水250 mL中，1次/d。治疗组在对照组治疗的基础上静脉滴注醒脑静注射液，20 mL加入到生理盐水250 mL中，1次/d。两组患者均连续治疗14 d。观察两组的临床疗效，比较两组的血液流变学、内皮指标因子水平、美国国立卫生研究院卒中量表（NIHSS）评分。结果 治疗后，对照组和治疗组的总有效率分别为75.00%、90.00%，两组比较差异有统计学意义（P<0.05）。治疗后，两组全血黏度（WBV）、血浆黏度（PV）、血细胞比容（HCT）、红细胞聚集指数（RF）水平均较治疗前明显下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组血液流变学指标水平显著低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组单核细胞趋化蛋白-1（MCP-1）、内皮素-1（ET-1）、血小板活化因子（PAF）水平均明显降低，而一氧化氮（NO）、胰岛素样生长因子-1（IGF-1）水平均较治疗前明显增加，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组内皮指标因子水平明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者NIHSS评分均较治疗前明显下降，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组NIHSS评分显著低于对照组，两组比较差异有统计学意义（P<0.05）。结论 醒脑静注射液联合胞磷胆碱钠注射液治疗急性脑梗死具有较好的临床疗效，可改善血液流变学和疾病相关指标，增强血管内皮功能，降低炎症反应，具有一定临床推广应用价值。

Objective To explore the clinical effect of Xingnaojing Injection combined with Citicoline Sodium Injection in treatment of acute cerebral infarction. Methods Patients (120 cases) with acute cerebral infarction in Dechang County People's Hospital from August 2016 to March 2018 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Citicoline Sodium Injection, 0.5 g added into normal saline 250 mL, once daily. Patients in the treatment group were iv administered with Xingnaojing Injection on the basis of the control group, 20 mL added into normal saline 250 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and hemorheology, endothelial marker factors, and NIHSS scores in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 75.00% and 90.00%, respectively, and there was difference between two groups (P<0.05). After treatment, WBV, PV, HCT, and RT in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the hemorheology indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of MCP-1, ET-1, and PAF in two groups were significantly decreased, but the levels of NO and IGF-1 in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the endothelial marker factors levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, NIHSS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the NIHSS scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Xingnaojing Injection combined with Citicoline Sodium Injection has clinical curative effect in treatment of acute cerebral infarction, can improve hemorheology and disease-related indicators, enhance vascular endothelial function, and reduce inflammation reaction, which has a certain clinical application value.

R971